AbbVie, schizophrenia

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie shares are down 12.4%. In a statement, AbbVie said that its Phase 2 trial investigating ...
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market for new treatments for the condition.
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic
Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug trial failed to meet their primary endpoint. AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily,
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.
STAT2h
Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...
My Favorite Dividend King to Buy in November
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
AbbVie: 3 Positives From The Earnings Report
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...
Nasdaq10d
Is AbbVie (NYSE:ABBV) Stock a Buy After Its Dividend Hike?
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...
The Pharma Letter10d
AbbVie inks up to $1.4 billion deal with EvolveImmune
This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...
Crain's Chicago Business11d
AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate
Biotherapeutic firm EvolveImmune Therapeutics gets $65 million upfront and potentially $1.4 billion more if drugmaker AbbVie licenses its T-cell therapy.
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...
The Pharma Letter10d
AbbVie and Gedeon Richter partner on neuropsychiatric conditions
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to ...
Yahoo Finance2d
Investing in AbbVie (NYSE:ABBV) five years ago would have delivered you a 179% gain
But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price of AbbVie Inc.